Table 5.
Comparison of the characteristics and effects of MRAs.
| Steroidal MRA | Non-Steroidal MRA | ||
|---|---|---|---|
| Characteristics | Spironolactone | Eplerenone | Finerenone |
| Antagonism over MR | High | Low | High |
| Antagonism over AR | High | Low | Low |
| Effect on proteinuria and kidney damage | Moderate | Low | High |
| BP reduction | High | Low | High |
| Effect on HFpEF | Moderate | Moderate | High |
| Effect on HFmrEF | Moderate | Moderate | High |
| Effect on HFrEF | High | High | High |
| Hyperkalemia | High | Moderate | Low |
| Gynecomastia | High | Moderate | Low |
MRA = mineralocorticoid receptor antagonist; MR = mineralocorticoid receptor; AR = androgen receptor; BP = blood pressure; HFpEF = heart failure with preserved ejection fraction; HFmrEF = heart failure with moderately reduced ejection fraction; HFrEF = heart failure with reduced ejection fraction.